J&J commits $785M to in vivo CAR-T development

J&J is backing Sail's in vivo CAR-T work in a deal that could point toward a buyout of the cell therapy approach.

Johnson & Johnson has committed $785 million to advance Sail's work on in vivo CAR-T therapy, according to the metadata for this signal. The arrangement is described as potentially charting a path toward a buyout, meaning the deal may deepen if the approach proves out. This is early-stage: the work is in development, not on the market.

Current CAR-T treatments are made by extracting a patient's own cells, engineering them outside the body, and reinfusing them. That bespoke manufacturing is slow and expensive. In vivo CAR-T aims to do the engineering inside the body directly, which would remove much of that custom production and, in principle, lower the cost and widen access to cell therapy.

If off-the-shelf cell therapy can be delivered without per-patient manufacturing, a class of treatment that has been priced out of reach for most could become far cheaper and more available. That is the reason a deal at this scale matters for the health need, even at this stage.

The fact sheet for this item was not available, so the details here rest on the metadata line alone. The size of the commitment, the parties, and the terms of any possible buyout sit with the original reporting from Fierce Biotech, which readers should consult for specifics.

Source: Fierce Biotech